Bank of America spends more than $250 million on GLP-1s
CEO Brian Moynihan said he knows some employees will leave before reaping the health benefits.
Bank of America has allocated more than $250 million annually to purchase GLP-1 weight-loss drugs for its 210,000 employees, according to CEO Brian Moynihan. The investment is part of the bank's long-term strategy to enhance employee health and minimize health-related risks. Moynihan emphasized the positive impact on employees and the company's commitment to providing benefits. The firm's overall healthcare expenditure is approximately $2 billion.
However, corporate health benefits surrounding GLP-1s are not without challenges. Only 36% of companies offer coverage for these medications, according to a 2026 survey from the International Foundation of Employee Benefit Plans. Some major employers, such as PwC, have discontinued coverage for weight loss drugs. The emerging issue of employers grappling with the financial and personal health ramifications of GLP-1s has led to HR complications.
GLP-1s are revolutionizing corporate healthcare budgets, but the financial burden and HR implications are becoming increasingly complex. Americans relying on these drugs have faced difficulties paying for them after changes in insurance coverage, highlighting the delicate balance between financial stability and physical well-being.
Written by urgent.news from Business Insider's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
